News & Stories

The Hong Kong University of Science and Technology (HKUST) has been appointed by the Asia Pacific Observatory on Health Systems and Policies (APO), a collaborative partnership hosted by the World Health Organization (WHO)’s Regional Office for the Western Pacific, to spearhead a regional research consortium focused on digital health innovation. This prestigious appointment, secured through a competitive process, underscores HKUST’s global leadership in policy research under the theme “Leveraging Digital Health Technologies and Data to Strengthen Health System Outcomes.”

The Hong Kong University of Science and Technology (HKUST) has shone in the second round of Research, Academic and Industry Sectors One-plus (RAISe+) Scheme launched by Innovation and Technology Commission’s (ITC), securing grants for seven teams – the highest number among local institutions.  The seven funded projects encompass a diverse array of innovative research and development efforts. Three projects focus on health and medical innovation, addressing areas spanning diagnostics, medical treatment and gene therapy.  Three others focus on AI chips, semiconductors and their materials, while the remaining one explores novel displays and optoelectronic technology.

SmartCare Technology Co. Limited (SmartCare), a Healthtech innovator nurtured by The Hong Kong University of Science and Technology (HKUST) joins hands with CUHK Medical Centre (CUHKMC) to announce a significant partnership aimed at advancing healthcare delivery through innovative artificial intelligence (AI) solutions. The Memorandum of Understanding (MoU) signing ceremony marks a strategic commitment to co-develop AI technology solutions for healthcare settings. This collaboration will harness SmartCare’s expertise in healthcare AI technology and CUHKMC’s commitment to providing exceptional healthcare services. The partnership aims to implement advanced AI technology to enhance clinical workflows, improve patient care, and streamline operational efficiency within CUHKMC’s facilities.

The Hong Kong University of Science and Technology (HKUST) and AstraZeneca Hong Kong (AstraZeneca) today announced the signing of a Memorandum of Understanding (MoU) to build on their long-standing partnership, aiming to accelerate research and development (R&D) and drive innovation in the city’s life sciences ecosystem. The signing ceremony was held at the HKUST Unicorn Day 2025, an occasion where entrepreneurs, investors, and industry leaders come together for technological knowledge exchange and collaboration. Witnessed by President of HKUST and the Morningside Professor of Life Science, Prof. Nancy Ip and General Manager of AstraZeneca Hong Kong and Macau Ms. Shan Wu, the MoU was officially signed by Vice-President for Research and Development at HKUST, Prof. Tim Cheng and Head of Medical Affairs, BioPharmaceuticals & Rare Disease of AstraZeneca Hong Kong Mr. Tin Hung Wong.  

  In a world still grappling with the aftermath of the COVID-19 pandemic, health disparities are widening and healthcare worker shortages persist, revealing vulnerabilities in our health systems. “Yet within all these challenges lie immense opportunities for collaboration and innovation,” noted Professor Nancy IP, President of The Hong Kong University of Science and Technology (HKUST), at the 2025 Asia Summit on Global Health. As a keynote panelist, she asserted that universities can play a pivotal role in shaping a more equitable and sustainable health system. 

The Hong Kong University of Science and Technology (HKUST) has emerged as the top-performing local institution in the second round of the Innovation and Technology Commission’s (ITC) Research, Academic and Industry Sectors One-plus (RAISe+) Scheme, securing funding for seven projects. Spanning health and medical sciences, artificial intelligence (AI) and robotics, advanced manufacturing, and electrical and electronic engineering, these projects underscore HKUST’s leadership in transforming pioneering research into real-world applications.

The Hong Kong University of Science and Technology (HKUST) announced today that  its School of Engineering researchers have developed Mixture of Modality Experts (MOME), a groundbreaking large artificial intelligence (AI) model for non-invasive breast cancer diagnosis. Trained on the China’s largest multiparametric MRI (mpMRI) breast cancer dataset, MOME achieves expert-level accuracy in classifying tumor malignancy, comparable to that of radiologists with five+years of experience. This innovative solution is now undergoing extensive clinical validation across more than ten hospitals and partner institutions, including Shenzhen People’s Hospital, the Guangzhou First Municipal People's Hospital, and Yunnan Cancer Center, to validate its effectiveness and ensure real-world applicability. Harnesses China’s largest mpMRI Dataset

A Hong Kong University of Science and Technology (HKUST) research team led by Prof. SUN Jianwei and Prof. LIN Zhenyang from the Department of Chemistry has developed a catalytic enantioselective type II [5 + 2] cycloaddition method to address the challenges of synthesizing chiral bridged polycyclic structures, particularly those with a bridged seven-membered subunit. This innovative approach utilizes 3-oxidopyrylium ylides to create the desired complex shapes, paving the way for more applications in the rapid synthesis and diversification of other valuable complex molecules, including important natural products and drug molecules. Chiral bridged polycyclic structures, particularly those bearing a bridged seven-membered subunit, represent a complex and intriguing molecular architecture found in many natural and biologically significant compounds. However, synthesizing these structures has posed substantial challenges for chemists.